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Essential hypertension is a complex trait where
the underlying aetiology is not completely under-
stood. Left untreated it increases the risk of severe
health complications including cardiovascular and
renal disease. It is almost 15 years since the first
genome-wide association study for hypertension,
and after a slow start there are now over 1000 blood
pressure (BP) loci explaining ∼6% of the single
nucleotide polymorphism-based heritability. Suc-
cess in discovery of hypertension genes has pro-
vided new pathological insights and drug discovery
opportunities and translated to the development of
BP genetic risk scores (GRSs), facilitating popula-
tion disease risk stratification. Comparing highest
and lowest risk groups shows differences of 12.9
mm Hg in systolic-BP with significant differences
in risk of hypertension, stroke, cardiovascular dis-
ease and myocardial infarction. GRSs are also
being trialled in antihypertensive-drug responses.
Drug targets identified include NPR1, for which an
agonist drug is currently in clinical trials. Identifi-
cation of variants at the PHACTR1 locus provided
insights into regulation of EDN1 in the endothe-
lin pathway, which is aiding the development of
endothelin receptor EDNRA antagonists. Drug re-
purposing opportunities, including SLC5A1 and
canagliflozin (a type-2 diabetes drug), are also
being identified. In this review, we present key
studies from the past, highlight current avenues
of research and look to the future focusing on gene
discovery, epigenetics, gene-environment interac-
tions, GRSs and drug discovery. We evaluate lim-
itations affecting BP genetics, including ancestry
bias and discuss streamlining of drug target dis-
covery and applications for treating and prevent-
ing hypertension, which will contribute to tailored
precision medicine for patients.
Keywords: drug targets, epigenetics, essential hyper-
tension, gene x environment, genetic risk score,
genome-wide association study
INTRODUCTION
Hypertension is the leading global risk factor for
morbidity and mortality, and studies have demon-
strated a clear link between elevated systolic and
diastolic blood pressure (BP) and cardiovascular
disease (CVD) [1]. In 2015, around 7.8 million
deaths were attributed to hypertension [2], and
the number of individuals diagnosed with hyper-
tension is estimated to reach 1.5 billion globally
by 2025 [3]. The current guidelines proposed by
the European Society of Cardiology characterise
grade 1 hypertension clinically as ≥140/90 mm
Hg in patients below 80 years [4], while the clini-
*These authors contributed equally to this work.
cal threshold defining hypertension in the United
States is lower at ≥130/80 mm Hg, as stated
by the American Heart Association [5]. Approx-
imately 95% of hypertensive cases are termed
as essential hypertension (EH); hypertension with
an unknown cause resulting from interplay of
environmental and genetic factors. The remaining
5% of cases are grouped as secondary hyperten-
sion, of which 1% are monogenic disorders [6].
Despite extensive research, BP regulation mecha-
nisms and hypertension pathophysiology remain
poorly understood, and there are issues in var-
ied patient response and adherence to current
pharmacological therapies. For decades, genomic
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research into hypertension and BP has provided
clues into its complex genetic architecture in a bid
to identify novel target mechanisms for therapeu-
tics and personalised medicines.
HISTORY OF BP GENETICS, EARLY STUDIES AND RESULTS
In 1949, Page documented the multifaceted
nature of EH as a result of the dysregulation
of four integral systems: cardiovascular, renal,
endocrine and neural [7]. The genetic contribution
to hypertension was recognised 32 years later in
his revision of the Mosaic Theory of Hyperten-
sion [8], following evidence from a multitude of
familial studies [9–11] and the characterisation of
rare monogenic disorders of hypertension [12,13].
With a consensus on the existence of a genetic
component of BP, the Platt v. Pickering debate of
the 1950s considered whether hypertension was a
monogenic or polygenic disorder [14]. Platt argued
that rare monogenic disorders of hypertension
were evidence for a monogenic nature. In contrast,
Pickering postulated the Gaussian, rather than
bimodal, distribution of BP throughout the popu-
lation suggested BP is determined by a collection
of genes and further recognised hypertension as
a quantitative trait with a normal distribution,
opposing the previous suggestion of hypertension
as a qualitative trait distinct to normotensive BP
[14]. Later studies supported the polygenic nature
of hypertension and estimated the heritability of
clinical systolic BP (SBP) and diastolic BP (DBP) to
be 15%–40% and 15%–30% respectively [9], with
rare monogenic disorders representing an extreme
end of the distribution.
The Human Genome Project provided the catalyst
for advances in gene mapping in the 1990s [15].
Linkage analysis was a key tool in the early years,
where microsatellite genetic markers were tested
for co-segregation with a trait in families, the
results of these studies provided chromosomal
locations of genes for traits [6]. Investigation into
families with monogenic disorders of hypertension
using linkage analysis facilitated the identification
of the first BP-associated genes and highlighted
the role of renal and adrenal pathways in BP
control, as covered extensively by Raina et al [12].
Lifton and colleagues were responsible for the
majority of research into monogenic disorders of
hypertension in the 1990s - of note, research on
patients with Liddle syndrome identified gain-of-
function mutations in SCNN1B and SCNN1G genes
encoding subunits of the epithelial sodium chan-
nel (ENaC) present on collecting ducts of kidneys,
establishing the role of renal sodium reabsorp-
tion in BP control [13]. Yet monogenic forms of
hypertension account for a very small percentage
of hypertensive cases, and in a bid to elucidate
genes involved in polygenic forms of hypertension
a series of candidate-gene linkage studies were
carried out in familial cohorts [16–22]. These stud-
ies yielded some promising results; however, these
were often contradictory across cohorts with no
single candidate gene consistently showing strong
linkage with hypertension. Notably, variants of the
AGT gene encoding angiotensinogen, a key player
in the renin-angiotensin system of BP control,
were linked to hypertension in a linkage-analysis
of 63 white European families [19]; this result
was not replicated in a larger European study
of 350 families [20]. Linkage at this locus was
subsequently demonstrated across populations,
in African-Caribbean [18], Mexican-American
[17] and Japanese [21] cohorts, albeit a different
variant, but not in others [16], highlighting there
may be potential variation between ethnicities.
Candidate-gene studies were generally underpow-
ered as they relied on familial cohorts for which
recruitment is difficult, and there was a lack repli-
cation data, especially from non-white European
populations [23]. Furthermore, candidate genes
were selected based on previously characterised
BP pathways restricting the identification of novel
BP genes. At the turn of the 21st century, genome-
wide linkage analyses were deployed with the
aim of identifying loci anywhere in the genome, a
hypothesis free approach. Various genome-wide
linkage analyses were undertaken in relatively
large cohorts including the Framingham Heart
Study [24], the Family BP Program [25,26] and the
British Genetics of Hypertension (BRIGHT) study
[27]. These studies successfully identified a num-
ber of quantitative trait loci (QTLs) (regions of DNA
linked to variations in the phenotype) associated
with hypertension, some of which were validated
in follow-up studies [28–30]. The identification
of broad QTL regions on five chromosomes led
the BRIGHT study to propose hypertension as an
’oligogenic’ disorder, in which a small number of
genes located in these regions provide the largest
effect on the trait, with additional genes exerting
smaller effects [27]. Nonetheless, interpreting
linkage analysis results presented challenges and
limitations; the QTLs identified spanned broad
regions of DNA making the identification of the
responsible gene difficult [6], and there was a
lack of power to identify variants with smaller
effects [31].
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Alongside studies in human populations, rodent
models have also been studied, and these have pro-
vided a valuable resource for understanding the
polygenic nature of EH. Importantly, genetically
modified mouse models have been instrumental for
functional analysis and validation of BP candidate
genes [32]. The inbred spontaneous hypertensive
rat (SHR) strains have been effective for identifying
novel genes and also providing useful physiologi-
cal models of CVD, as well as a valuable tool for
analysis of therapeutic efficacy and toxicity of can-
didate drugs [33]. The SHR family is composed of
several lines of selectively inbred rats, each carry-
ing a different genotype and expressing combina-
tions of traits observed in human EH, as a whole
mimicking the human clinical phenotype [33–37].
Prior to the complete sequencing of the rat genome
[32], linkage analysis in these rat strains identified
over 270 QTL regions associated with hypertensive
traits, predominantly located on four chromosomes
[34], in line with the oligogenic theory of hyper-
tension [27]. Studies in the rat have some bene-
fits over human studies as the genetic heterogene-
ity of rat strains, and their environment are easily
controllable, increasing study power. Nonetheless,
similar to linkage analysis in humans, these stud-
ies were limited by their sample sizes, and map-
ping the QTL regions to identify candidate genes
remained a difficult task. Concurrent sequencing
of the rat [38] and human [15] genomes provided
an opportunity for comparative mapping between
species, facilitating more accurate translation of
QTL regions from rat studies to humans [33]. We
now know that some QTL regions identified with
linkage analysis in humans validate in congenic rat
strains, this is a topic covered extensively by Pad-
manabhan and Joe in 2017 [39]. Notably, a meta-
analysis of microarray data from SHR identified
several genes associated with BP in the rat [40].
A number of the identified genes had previously
been associated with hypertension in humans via
linkage-analysis or genome-wide scanning, includ-
ing APOE [41], NPPA and NPPB [42], corroborating
the role of these genes in BP control.
THE GWAS ERA – COMMON AND RARE VARIANT DISCOVERY
The complete sequencing of the human genome
in 2003 [15], paired with the development of sin-
gle nucleotide polymorphism (SNP) chip arrays
enabled cost-efficient high-throughput genotyping
of selected variants and powered the first genome
wide association studies (GWAS) [43–48]. SNPs are
single base variations in the genome which occur
at different frequencies in the population. In GWAS
SNPs distributed across the genome are tested for
association with traits or diseases. GWASs have
benefits over linkage analysis and candidate gene
studies as they are unbiased, permit larger sam-
ple sizes and enable meta-analyses improving sta-
tistical power [49]. The first GWASs for hyper-
tension yielded disappointing results, and no sig-
nificant loci were found [43,48]. A year later in
2008, the first locus (ATP2B1) significantly asso-
ciated with BP was identified in a GWAS of 1484
Japanese individuals [50]. This result was repli-
cated in a Korean cohort of >8000 individuals [51]
and in a large European ancestry cohort of nearly
30,000 individuals [45]. Over the following years,
many investigators using GWAS have identified loci
for the quantitative traits of systolic, diastolic and
pulse pressure [52], facilitating the discovery of
novel BP pathways.
SNP arrays include only a small proportion of the
variants present in the genome. The development of
SNP reference panels, including the 1000 Genomes
Project [53] and the Haplotype Reference Consor-
tium [54], enabled imputation and estimation of
the effects of associated SNPs not featured on
arrays. In tandem with SNP arrays, the establish-
ment of accessible large-scale Biobanks (e.g., UK
Biobank) containing not only genetic data but a
variety of phenotypic and health-related data [55]
has improved the statistical power of GWAS and
enabled the detection of both common and rare BP
variants [41,56–58]. The first GWASs were powered
for the detection of common variants; these have
relatively small effect sizes on BP ranging 0.5–1
mm Hg per allele. With increasing access to sam-
ples, imputation and sequencing data, investiga-
tors have also focused efforts on identifying low fre-
quency and rare variants (minor allele frequency
< 1%) which have larger effect sizes (around 1.5
mm Hg per allele). In 2011 the Exome chip was
launched [59]; an array of predominantly rare and
low frequency variants mostly located in exonic
(coding) regions. Four years later, a trans-ethnic
meta-analysis of Exome chip data with replication
in European and South Asian ancestries identified
the first rare exonic variants associated with BP
traits with effect sizes greater than that observed
with common variants (>1.5 mm Hg per allele),
mapped to four genes: RBM47, COL21A1, DBH and
RRAS. In the same year, an additional trans-ethnic
study reported a rare variant of the NPR1 gene,
associated with a +1.1 mm Hg increase in SBP;
this gene is a drug target for hypertension with a
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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clinical trial ongoing (Figure 1) [57]. Nonetheless,
the collective number of loci identified at this point
accounted for 2.8% of the genetic heritability of BP.
It was not until 2018 that the impact of large-scale
Biobanks was truly demonstrated, with the identi-
fication of over 500 novel loci in a single study of
one million individuals of European descent, dou-
bling the total explained heritability from less than
3% to ∼6% [58]. More recently in 2020, a study
including 1.3 million individuals using Exome chip
data with replication in trans-ethnic individuals
identified an additional 106 novel loci, of which 87
were rare variants [56]. To date, over 1000 loci have
been significantly associated with BP, with con-
tinuous efforts being made to further unravel the
genetic architecture of BP. However, elucidating
the causal SNPs remains a challenge; the majority
map to noncoding regions of the genome, and vari-
ants are often in linkage disequilibrium (LD) with
one or more other variants, in which they are non-
randomly associated in the population.
GWASs BEYOND EUROPEAN ANCESTRY
Whilst BP genetic discovery projects continue to
expand in size, they have maintained a strong
bias for centring on individuals of European
ancestry, and thus there is limited representation
and results from other ancestral backgrounds.
This is in part due to recent studies including
samples from the UK Biobank which is largely
European [55], with cumulative estimates of
Europeans contributing 88.45% genotypes to
GWASs across all traits in 2020 [60]. In order
to have GWAS results that are impactful across
populations, this data gap needs to be addressed.
Continuing this ancestral bias in genetics could
exacerbate health disparities due to ethnicity and
miss the benefits of new discovery opportuni-
ties and understanding in an inclusive system.
African ancestry individuals have the highest
age-adjusted prevalence of hypertension [61].
Downstream issues are already occurring due to
ancestral bias; using genetics for risk stratification
of cardiomyopathy wrongly miscategorises some
African Americans due to their omission from
control cohorts [62]. This demonstrates the impor-
tance of interrogating the population-specificity
of identified variants. Research across ances-
tries is increasing, either through sampling less
studied populations or conducting trans-ethnic
studies [41,63]. These studies have discovered
novel and ancestry specific loci, although they
are often limited by smaller sample sizes in com-
parison to European-based research [64]. An
increase in diverse sampling is being addressed
by ongoing establishment of national biobanks
(H3Africa, BioBank Japan, the Korean Biobank,
the African Genome Variation Project,
Qatar Biobank and GenomeAsia 100k), and
these datasets are being increasingly utilised in
genomics research [65,66].
RISK PREDICTION AND CAUSAL MECHANISMS
As BP GWAS summary statistics and other
datasets become publicly available to researchers
(ebi.ac.uk/gwas/, genetics.opentargets.org/,
phenoscanner.medschl.cam.ac.uk/), new meth-
ods for interpreting and translating these data
have been developed for clinical applications and
biological interpretation of findings.
Risk prediction modelling for CVD is now includ-
ing genetic biomarkers. Genetic risk scores (GRSs)
can be developed from combining significant risk
alleles identified from GWAS. Alternatively, a more
complex polygenic risk score (PRS) can be created
by combining a broader range of SNPs which may
not individually reach genome-wide significance
but together provide an improved risk score [67].
One recent BP-GRS developed in UK Biobank (n
= 392,092) combining 901 SNPs found a differ-
ence of 12.9 mm Hg (SBP) and 7.5 mm Hg (DBP)
between the lowest risk decile and the highest risk
decile along with a trebled risk of hypertension and
an increased risk of stroke, CVD and myocardial
infarction [58]. The authors of this study indicated
such a risk score may have utility for early iden-
tification of individuals, at a time where lifestyle
factors could be advocated to reduce BP levels.
PRSs have also been used to test for responsive-
ness to different drug classes. One such recent
study evaluated the association of a genome-wide
PRS (>1 million SNPs) with antihypertensive drug
responses. This was conducted across four BP drug
classes based on data with a sample of n∼200 per
drug using BP data before and after 4 weeks on
monotherapy; however no association was estab-
lished [68]. Utilising risk scores in this way is
an area of research in its infancy, and this is
reflected in the small sample sizes studied and
consequently lower power which could influence
the results obtained so far. Increased sample sizes
would be important to account for any BPmeasure-
ment variance. Furthermore, the studies in this
area are predominantly conducted in individuals
from European ancestries, potentially leading to
4 © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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effectiveness issues across ethnicities due to the
intrinsic limitations of the PRSs [69].
Alongside the development of risk scores,
Mendelian randomization (MR) is being applied
widely to determine causal effects using genetic
data to mimic a randomized controlled trial [70].
The MR framework uses SNPs to overcome issues
with traditional observational studies such as
bias due to confounders and reverse causation.
As a random assortment of alleles is passed onto
offspring independent of any other characteristics,
SNPs in a given population should be similar in
all other characteristics removing any potential
confounders [70]. Since inception, MR has been
regularly applied to genetic data to identify causal
risk factors, drug evaluation and identifying dis-
ease mechanisms. A recent MR study used a
novel approach to assess whether repurposing
antihypertensive drugs would affect the risk of
Alzheimer’s disease [71]. The study was conducted
using SNPs in genes associated with 12 antihy-
pertensive drug classes. The selection of SNPs
was based on data from www.drugbank.ca/ and
www.gtexportal.org/, and these were validated in
a UK Biobank SBP GWAS cohort (n = 317, 754),
and the effect was estimated in an Alzheimer’s
disease GWAS (n = 17,008/37,154 case/control).
The results indicated lowering SBP via the anti-
hypertensive drug targets selected was unlikely to
affect the risk of developing Alzheimer’s disease.
This work provides a blueprint for evaluating
antihypertensive drug applications without con-
ducting a full randomized controlled trial [71].
In another example, Richardson and colleagues
used the principles of MR to study the association
of the transcriptome across 48 tissue types with
complex traits to identify candidate genes loci
[72]. Their analysis applied to BP data identified
possible causal associations, for example one SNP
(rs1706003) which may have been overlooked by
using GWAS data alone indicated the candidate
gene ATP13A3 [72]. These methods serve as a
reminder that a variety of approaches are available
and are being constantly developed with numerous
applications to utilise and interpret results from
genetic studies.
Determining candidate genes and mechanisms at
BP loci is key for translation to druggable targets.
Before the advent of GWAS, genes andmechanisms
for BP were mostly discovered using rat or mouse
models. Now, GWAS is taking centre stage, and
combining their results with experimental models
provides additional support for drug development
as illustrated by NPR1 (Figure 1).
As mentioned previously, GWASs do not provide
the causal variant or gene. Functional studies
using mouse models remain a key experimental
tool once a gene is identified as having strong sup-
port from bioinformatics analysis. A recent exam-
ple of follow-up of GWAS loci is demonstrated
with the identification of ARHGAP42 (Rho GTPase
Activating Protein 42) as the result of the SNP
rs633185 reported as a lead variant at this locus in
a GWAS [73]. Genetically modified mice were used
to establish that ARHGAP42 deficiency results in
hypertension via increased response to angiotensin
II and endothelin-1 [74]. These models are continu-
ing to be applied to assess whether this candidate
gene could be a valid drug target moving forward
[75]. Nonetheless, functional validation represents
a major challenge due to the large number of SNPs
associated with BP. Candidate genes from GWAS
can be evaluated using ’in vitro’ systems, including
techniques such as CRISPR which can be used for
gene-editing of BP variants and subsequent test-
ing in cellular models. Alternatively, mechanisms
for GWAS ’candidate genes’ can converge from oth-
ers work studying known BP mechanisms. For
example, the variant rs880315 located within an
intron of CASZ1 (Castor Zinc Finger 1) is associated
with hypertension in GWASs and replicates across
different populations and ancestries [45,76,77]. A
recent study has established that CASZ1b (short
form of CASZ1) co-localises with the mineralocor-
ticoid receptor in the kidneys and is part of an
aldosterone-dependent corepressor complex sup-
pressing ENaCα and SGK1 which are linked to ele-
vating BP by promoting sodium reabsorption [78].
GENETICS PRIMING DRUG DISCOVERY
Developing new drug treatments for EH is a key
driver of BP genetics research. Increasing our
armoury of therapies that effectively lower BP
with minimal side effects and reduce hypertension-
associated CVD is important for personalised
medicine. This is particularly necessary for hyper-
tension as there are a large proportion of indi-
viduals that do not respond to current treat-
ments. Evangelou et al reported five loci (PKD2L1,
SLC12A2, CACNA1C, CACNB4 and CA7) contain-
ing genes which are drug targets for several known
antihypertensive drug classes [58]. These genes
strongly validate the genetic approach of iden-
tifying potential drug targets. With greater than
6 © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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1000 BP-associated loci now identified and genetic
data being collected each year, the list of possi-
ble drug-target genes is continuously expanding.
For example, in 2020 Surendran et al reported
23 genes as potentially druggable [56]. However,
only 12 of the potentially druggable genes iden-
tified by Evangelou et al are the focus of clinical
trials for BP (Table 1), including the gene EDNRA.
EDNRA encodes endothelin receptor A which plays
a role in the endothelin pathway, an established
mechanism of BP control (Figure 2). Although,
EDNRA can be considered as a drug-target this is
mentioned with caution, as currently endothe-
lin receptor antagonists that are used clinically
to treat pulmonary hypertension have had road-
blocks when reaching clinical applications for EH
[79]. There are also druggable genes not identified
initially via GWAS but from other genetic stud-
ies which are in development, including the gene
MTHFR (Figure 3). Work is in progress to vali-
date the mechanism by which MTHFR potentially
impacts BP. It is hoped that some of these discov-
eries will translate to novel therapeutics.
Alongside identifying new therapeutic targets,
genetics also provides insight into opportunities
for drug repurposing. Evangelou et al and Giri
et al both curated lists of potential gene-drug
interactions and identified genes with drug-targets
with repositioning potential for BP (e.g., MARK3,
PDGFC, TRHR, ADORA1, GABRA2, VEGFA, PDE3A
and SLC5A1 noted by Evangelou et al and PDE3A,
PSMB9 and SH2B3 noted by Giri et al) [41,58]. One
of the strongest contenders was SLC5A1, the target
of canagliflozin. Canagliflozin is a SGLT2 inhibitor
and originated as a therapeutic for type-2 diabetes.
It has since been licensed for treatment in heart
failure. Canagliflozin decreases glucose reabsorp-
tion but also reduces BP in diabetes patients, indi-
cating potential as an anti-hypertensive therapeu-
tic [58].
Pathway enrichment analysis is a post-GWAS test
which can provide mechanistic insights and high-
light organ systems and signalling pathways which
could be therapeutically targeted. Notably from
BP GWASs there is enrichment of genes in arter-
ies, and TGF-ß and Notch signalling pathways
are indicated [41,56]. However, a lack of enrich-
ment in other tissues, including the kidneys which
are heavily involved in BP regulation, highlights
caveats in tissue enrichment analysis (noting there
are limited kidney samples in public datasets) [41].
Nevertheless, pathway analyses have successfully
reported genes associated with BP and other CVD
pathophysiologies, including PHACTR1, informing
possible interplay between disease mechanisms
[41].
RESISTANT HYPERTENSION
Resistant hypertension, defined as high BP despite
patients being on three antihypertensive drug
classes [80], is not as well studied using genetic
approaches. This is in part due to the fact that
resistant hypertension is a complex clinical entity,
in which resistant hypertension is also used as an
umbrella term for any elevated BP that is nonre-
sponsive where you can rule out nonadherence and
secondary causes. This phenotype can result from
a large range of diverse pathophysiologic sources
and thus poses a great challenge for reliably iden-
tifying significant findings in genetic studies. Fur-
thermore, BP GWASs have focused heavily on
quantitative BP phenotypes as described therein;
however in recent years GWASs for resistant hyper-
tension have been performed [81,82], with some
new findings. For example, Rouby et al performed,
to the best of our knowledge, one of the first GWAS
for resistant hypertension and used their findings
to develop a GRS [81]. The GRS was based on three
signals (in MSX2, IFLTD1 and PTPRD) that were
found in participants taken from two randomized
clinical trials (1194 White and Hispanic partici-
pants in the discovery stage from one clinical study
and 585 individuals in the replication stage from
an independent clinical study) [81]. The GRS is yet
to be tested with researchers noting there was no
cohort large enough at that time to study [81]. In
contrast, Irvin et al performed a resistant hyper-
tension GWAS, in which they replicated results in
new samples using the Million Veterans Program (n
= 16,833) with replication across different ethnic
groups and identified the CASZ1 locus with great-
est significance [82]. Specifically, they found that
rs12046278 T carriers in CASZ1, a locus also asso-
ciated with quantitative BP traits, were less likely
to have resistant hypertension [82]. Overall, these
findings emphasize resistant hypertension GWAS
is in its infancy and requires further research. New
findings have the potential to improve our under-
standing of resistant hypertension BP biology and
to optimize how BP drugs are prescribed.
BP GENETICS BEYOND GWAS - EPIGENETICS
Whilst GWAS has enabled the discovery of a large
number of loci, they only explain approximately
6% of BP SNP heritability thus far [58]. Epige-
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
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FIGURE 3 MTHFR: Uncovering novel blood pressure mechanisms. MTHFR has been a research topic since 2002 when
C677T polymorphism was identified [120], alongside research demonstrating an association of this variant with BP [44]. Its
actual BP mechanism however has remained elusive. Studies have shown MTHFR has a BP altering relationship with the
B vitamin riboflavin. (a) Riboflavin in its co-enzymatic form FAD is required as a cofactor for the MTHFR enzyme and was
found to stabilize the MTHFR enzyme in animal models with theMTHFR C677T polymorphism [121]. (b) This relationship has
since been explored in clinical trials investigating riboflavin supplementation and BP (ClinicalTrials.gov ID: NCT03151096,
NCT02463513). (c) Recently, Amenyah et al. [122] found individuals with the MTHFR 677TT vs CC genotype in response
to riboflavin had altered DNA methylation at several blood pressure genes (NOS3, ACE, GNA12 and AGTR1), suggesting a
potential mechanism by which riboflavin is able to lower BP, and indicating methylation affectsMTHFR’s impact, presenting
hypotheses for further epigenetic research
Abbreviations: BP, blood pressure; FAD, flavin adenine dinucleotide; MTHFR, methylenetetrahydrofolate reductase.
netic changes may also have an important role
in the heritability of BP and may explain some of
the heritability not accounted for by SNP varia-
tion. Epigenetic changes (modifications that lead
to changes in the expression of genes but do not
change the DNA sequence) can be both herita-
ble and modulated through environmental fac-
tors, for example nutrition [83]. Epigenetic mech-
anisms can alter the expression of specific genes
through various methods including DNA methy-
lation, which is often found at CpG dinucleotides
(cytosine and guanine bases connected via a phos-
phodiester bond) located in promoters of genes
[84]. Some known BP loci have already been shown
to act through epigenetic mechanisms (see the
PHACTR1 locus rs9349379 interaction with the
endothelin pathway in Figure 2). The development
of arrays targeting CpG sites has allowed the inves-
tigation of epigenetic BP regulation using EWASs
(epigenome-wide association studies). BP EWASs
are still in the early stages of exploration com-
pared to GWAS with only a small number of stud-
ies published each with limited sample sizes and
therefore low power. One of the largest BP EWAS
(17,010 individuals of European, African Ameri-
can, and Hispanic ancestry) reports 13 methyla-
tion loci which account for an additional 1.4%–2%
of heritable BP variation. The results were validated
14 © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Journal of Internal Medicine, 2021, 00; 1–23
Hypertension genetics past, present and future applications / Olczak et al.
in a cohort of 1516 individuals, along with 126 loci
identified after meta-analysis [85]. Another recent
EWAS has suggested potential ethnic differences in
methylated sites [86]; however this was based on
a significantly smaller sample size (n = 712 com-
prised of South Asian and European ancestries)
identifying eight loci (one present in both ethnici-
ties, seven European only). This study did not have
a validation cohort; however, it included a com-
parison between their results and the aforemen-
tioned study, which identified some overlap (e.g.,
cg19693031 near the TXNIP gene) with weaker
evidence of association compared to the previous
study. This in part could be due to both the smaller
sample size and the differing ethnic background of
this study (49% South Asian descent). Understand-
ing epigenetics and its contribution to hyperten-
sion is currently limited by technology. The current
array being used in EWASs covers <2% of known
CpG sites [87] as well as not detecting the effect
of other common epigenetic mechanisms such as
histone modification and non-coding RNA which
can also be seen work in tandem with each other
(for example lncRNA regulating DNA methylation
[88]). Further research in this area will be forth-
coming and will provide insights into how epige-
netics may mediate the relationship between BP
genetics, environmental factors and CVD.
GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS
There is a lot of on-going work investigating gene-
gene and gene-environment interactions, results
of which may advance our understanding of why
BP drugs are effective in only some patients and
aid the development of targeted drugs regulating
gene interactions. To the best of our knowledge,
BP gene-gene interactions have only been assessed
in a handful of small-scale studies [87,89,90].
For example, Meng et al found five novel inter-
actions (MAN1A1, LMO3, NPAP1/SNRPN, DNAL4
and RNA5SP455/KRT8P5) contributing to hyper-
tension [91]. However, this study only included
2203 cases with a matched number of controls
from a predominantly European dataset [91]. The
identified genes require further research to defini-
tively prove a link to BP modulation. There are also
several other similar studies with small datasets
(less than 1000 hypertensive cases per study
[87,89,91]). These studies have identified novel
interactions between known BP genes (for example
between MTHFR and FGF5 [89]). This work empha-
sizes a need for future work scaling up gene-gene
studies across populations for validation - from
which gene expression may be regulated as part
of more precise treatment as we gain better under-
standing of the interplay between genes.
There is more work on gene-environment interac-
tions. The goal of this approach is to understand
exactly how environmental factors (e.g., smok-
ing, alcohol intake, air pollution) interact with
genotypes to affect BP. These interactions may
lead to preventative medicine for at risk individ-
uals depending on modifiable environmental fac-
tors. In 2018, Rao et al, established the Gene-
Lifestyle Interactions Working Group to develop
robust investigation of gene-environment interac-
tions [92]. This working group provided a study
design that enables large-scale gene-environment
study and consists of 610,475 individuals from 124
cohorts [92], establishing a framework for future
study. A recent study by Sung et al included gene-
smoking interactions in their multi-stage GWAS,
finding 30 loci that were only associated with indi-
viduals of African ancestry [93]. Eight of these loci
had significant interactions with smoking status,
such as the CSMD1 locus which was also associ-
ated with BP in SHRs [93]. However, these loci were
only identified in the discovery stage of the study,
and, due to the small sample size of the African
individuals, replication was not possible [93]. The
results from this analysis and other studies [94]
further highlight a need for future work to incorpo-
rate larger sample sizes of non-European popula-
tions.
MINING POST-GWAS DATA
Post-GWAS methodology is advancing to meet
growing demands for analysis of large amounts of
genetic data. High-powered computational meth-
ods can account for SNP associations and their
annotations in-depth, guiding hypotheses for func-
tional follow-up, avoiding cherry-picking bias, and
dissecting past LD to the causal disease genes.
The methods being increasingly deployed range
from machine learning, network analysis, fine-
mapping, text-mining, MR and hybrid tools (Fig-
ure 4). Machine learning is a statistical method
using algorithmic rules to identify complex data
patterns and make predictions. It has had invest-
ment due to its ability to identify hidden pat-
terns within multi-omic data. Mishra et al have
used deep learning to identify the functionality
of BP SNPs, finding they had a higher likelihood
of appearing in CTCF-binding regions [95] – sites
that regulate transcription and enable chromatin
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loops. This method offers the ability to illuminate
details about the majority of BP SNPs found in
regulatory regions and provides evidence for lab-
oratory follow-up of select genes [95]. Machine
learning has also been used broadly across traits
to understand GWAS results (predicting epistatic
interactions, PRSs, or prioritizing variants/genes)
with potential for translational benefit. Paré et al
used machine learning to augment PRSs for poly-
genic traits, showing machine learning coupled
with summary-level GWAS data improved the R2
prediction of PRSs for height, body mass index and
diabetes [96]. These results suggest machine learn-
ing may also enhance PRSs for hypertension, indi-
cating its capability not only in understanding the
basic science of BP, as shown by Mishra et al, but
also as a translational tool. However, novel appli-
cations such as this are also limited - for example,
machine learning being a ’blackbox’ with lack of
explainability - indicating an advantage for devel-
oping hybrid methods. For example, Hemani et al
combined MR with machine learning for causal
inference post-GWAS, identifying causal variants
across 2407 phenotypes and creating a causality
map of the human phenome [97]. As innovative
methods such as these develop, their work paves
the way for future studies to extract higher level
information from amassing BP GWAS results and
sequencing data.
CHALLENGES AND OUTLOOK
Genetics research is starting to provide a more
comprehensive understanding of how individual
pathways and systems contribute to hypertension.
However, the specifics of how BP regulatory mech-
anisms interact with each other (e.g., epigenetic
factors acting in known BP pathways, gene-gene,
gene-environment, and gene-microbiome interac-
tions) is largely unexplored. A recent review by
Weber et al describes the regulation of hydrogen
sulfide metabolism and interactions with epige-
netic factors and gut microbiota and their contri-
bution to hypertension [98]. From their research
they put forward the theory that hydrogen sulfide
metabolism can be dysregulated and affect renal
function and BP, by gut microbiota (specifically
bacterial activity that increases urea blood concen-
tration) and microRNA modulation of angiotensin
II [98]. This study integrated results from multi-
ple modalities - epigenetics, metabolomics and the
microbiome - becoming one of the few studies plac-
ing pathway research into a broader picture of BP
biology. As research advances, intersectional stud-
ies such as this will need to become commonplace
and fitting into the overall paradigm of how genetic
studies are validated by research interlaying find-
ings from different studies, and extending their
insights into translational research for hyperten-
sion (Figure 5).
From a clinical perspective, increased access to
genetic data is providing many applications with
clinical utility. One example is the use of GRSs
for coronary heart disease (CHD) for prediction
and prevention of disease [99]. Kullo et al con-
ducted a clinical trial (n = 203) in participants
with no CHD. Participants were randomized to
receive a 10-year risk prediction using a clini-
cal risk score (CRS) alone or a CRS and CHD
GRS and results showed the latter group had
lower cholesterol levels and were more likely to
receive statins. This study had used shared deci-
sion making based on the patients overall risk
[99]. Recently a study by Weale et al developed a
PRS for atherosclerotic CVD including CHD [100].
They presented an integrated risk tool that per-
forms 10-year risk prediction across diverse eth-
nic and ancestry groups. They found improved
prediction of CHD across individuals of not only
self-reported White ethnicities but Black/African,
American/Black, Caribbean/Black, African and
South Asian (Indian, Bangladeshi or Pakistani)
ethnicities – with PRS effect sizes in these eth-
nicities being significant and of comparable size
to those seen in individuals of White ethnicities
[100]. These positive results provide for the first
time a validated PRS tool that can generalize across
ancestries and presents a roadmap example for
similar studies that may be appropriate for inform-
ing hypertension treatment using BP GRSs.
The pharmacogenetics of BP drugs, understand-
ing if a person’s drug response depends on genetic
influences, has also gained attention - but this is
an area which has room for improvement before
offering clinical potential. For example, Arnett et al
developed the GenHAT (Genetics of Hypertension
Associated Treatments) study, an investigation of
hypertension genetic variants and their interac-
tions with antihypertensive treatments in relation
to CHD [101]. This study was conducted over 4.9
years in 39,114 hypertensive cases across eth-
nicities – with individuals grouped depending on
their antihypertensive medication class – providing
one of the largest and most diverse pharmacoge-
netic BP studies. However, the results were not as
promising as expected, with, for example, results
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FIGURE 5 Key concepts on the path from gene discovery to clinical practice. Discovery and validation of candidate geneswas
initially done using linkage analysis in families (success story for monogenic disorders); GWAS and EWAS are the current
methods for gene discovery for essential hypertension. The discoveries from these experiments are being complemented
and expanded upon with epigenetic functional investigations, with further discovery science and interpretation using GxG
and GxE studies. For validation and interpretation of results to provide insights to causal mechanisms, approaches such as
Mendelian randomization, and machine learning methods are being applied and functional studies of candidate genes in
the laboratory. Validating hypertension mechanisms is leading to translational studies offering novel drug discovery, drug
re-positioning, application of PRSs for better risk stratification and PGx studies
Abbreviations: EWAS, epigenome-wide association study; GWAS, genome-wide association study; GxE, gene-environment
interactions; GxG, gene-gene interactions; PGx, pharmacogenetics; PRS, polygenic risk scores.
exploring AGT gene interactions across hyperten-
sion drug classes finding ‘no gene by treatment
interactions to be statistically significant’ [102].
This study and others suggest that the pharmaco-
genetics of BP requires further work, which aligns
with the overarching need for increased trans-
lational research before the genetics of BP can
provide clinical benefit and advance hypertension
treatments.
In conclusion, early genetic investigations of hyper-
tension successfully established rodent models
and advances in the human genome project
has permitted discoveries for genes causing both
monogenic forms of hypertension and EH. In recent
years new lines of genetic analyses have taken
shape, with epigenetics now being a hot topic.
However, whilst the genetic insights and progress
made so far have been vast, it is far from being
comprehensive. There are now large whole genome
datasets coming online and being collated into
databases such as in gnomAD [103], the UK
Biobank [55] and Genomics England’s 100,000
genomes project [104], which provide full coverage
of the genome at scale for the first time. Research
in hypertension is beginning to focus on non-
European data, as translational findings need to
benefit all populations equally and improve rather
than worsen existing health disparities. Research
also needs to expand in broader directions, span-
ning the metabolome, microbiome and incorpora-
tion of environmental factors. Such work will pro-
vide a more complete view of complex BP biology.
As intersectional experiments develop, they may
present an opportunity to connect findings with
growing gene-gene and gene-environment research
that may be the key to unlocking BP insights await-
ing discovery. Overall, the genetics of hypertension
is providing new information on underlying phys-
iology, it is building towards an endgame for pre-
cision medicine, that may ultimately lead to lower
BP as an important cofactor for decreasing CVD
and potentially offer large global impact.
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